
Dr. Agarwal’s Health Care Limited
Dr. Agarwal’s Health Care Limited(AGARWALEYE)
Total Shares
7,53,04,971
Issue Size
₹3027.26 C
Price Band
₹382 – ₹402
Lot Size
35 shares
Min. Investment
₹14,070
Max. Investment
₹14,070
Open Date
29 Jan, 2025
Close Date
31 Jan, 2025
Allotment
01 Feb, 2025
Listing
04 Feb, 2025
Max. Investment
₹14,070
Announced
29 Jan, 2025
Opening Date
29 Jan, 2025
Closing Date
31 Jan, 2025
Basis of Allotment
01 Feb, 2025
Initiation of Refunds
03 Feb, 2025
Credit of Shares
03 Feb, 2025
Listing Date
04 Feb, 2025
Live GMP
Est. Listing: ₹457
Apply via UPI in 5 minutes
Choose your broker • Zero commission on IPO
About Dr. Agarwal’s Health Care Limited IPO
Incorporated in 2010, Dr. Agarwal's Health Care Limited offers a comprehensive range of eye care services, including cataract and refractive surgeries, consultations, diagnoses, non-surgical treatments, and the sale of optical products, contact lenses, accessories, and eye care-related pharmaceutical items.
As of September 30, 2024, there were 737 doctors providing care to patients across the company's facilities. During this period, the company served 2.13 million patients and perform
Dr. Agarwal’s Health Care Limited IPO Share Price and Issue Size
Issue Breakdown
Shareholding
Dilution: 2.4% increase in shares
Dr. Agarwal’s Health Care Limited IPO Financials Health
Dr. Agarwal’s Health Care Limited IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| SHNI Maximum | 71 | 2485 | ₹9,98,970 |
| BHNI Minimum | 72 | 2520 | ₹10,13,040 |
| Retail Minimum | 1 | 35 | ₹14,070 |
| Retail Maximum | 14 | 490 | ₹1,96,980 |
| SHNI Minimum | 15 | 525 | ₹2,11,050 |
(All values in CR)
Dr. Agarwal’s Health Care Limited IPO Valuation
| Metric | Value |
|---|---|
| EPS Post IPO | 2.51 |
| EPS Pre IPO | 3.08 |
| P/E Post IPO | 160.48 |
| P/E Pre IPO | 130.44 |
| PAT MARGIN | 6.90 |
| PRICE TO BOOK VALUE | 7.96 |
| ROCE | 14.61% |
| ROE | 9.33% |
| RONW | 6.21 |
(All values in CR)
Strength & Risk of Dr. Agarwal’s Health Care Limited IPO
1. Largest eyecare services provider in India with a trusted brand.
2. End-to-end, comprehensive eyecare services offering.
3. Scalable, asset-light, hub-and-spoke operating model.
4. Proven clinical excellence driven by a strong clinical board and history of surgical innovations.
5. Doctor-promoters leading a team of qualified medical professionals and supported by an experienced management.
6. Proven track record of delivering organic growth, integrating and scaling acquisitions and improving operating profitability.
1. The company engage doctors through retainership arrangements and there is no assurance that its doctors will not prematurely terminate their arrangements with it. If the company is not able to attract and retain its doctors and other medical professionals, the company business, financial condition, results of operations and cash flows may be adversely affected.
2. The company business depends on the strength of the company brand equity and reputation. Failures to maintain and enhance its brand equity and reputation, including due to negative publicity, may adversely affect its business, reputation, financial condition, results of operations and prospects.
3. The company operates in a regulated industry, and its failures to comply with applicable safety, health, environmental, labor and other regulations, or to obtain or renew approvals, may adversely affect its business, reputation, financial condition, results of operations and cash flows.
4. A significant majority of its Facilities are located in the states of Tamil Nadu (in particular, Chennai), Maharashtra and Karnataka in India and any adverse developments in relation to these Facilities could adversely affect its business, financial condition, results of operations and cash flows.
5. The company is exposed to legal claims and regulatory actions arising from the provision of healthcare services and may be subject to liabilities arising from claims of malpractice and medical negligence which could adversely affect its business, financial condition, results of operations, cash flows, reputation and prospects.
6. Its international operations expose it to management, legal, tax, political and economic risks, and its failure to address such risks could adversely affect the company business, results of operations, financial condition and cash flows.
7. Its hub-and-spoke model may not be successful and the company may not be able to expand into new geographic regions, which could adversely affect its business, financial condition and results of operations.
8. The company has pursued and will likely continue to pursue strategic acquisitions for inorganic growth. Its inability to successfully identify, acquire and integrate suitable opportunities on commercially reasonable terms in the future could adversely affect its business, financial condition, cash flows and results of operations.
9. Its historical performance is not indicative of the company future growth or financial results and if its fail to manage the company growth or implement its growth strategies, the company business, financial condition and results of operations may be adversely affected.
10. The company is exposed to credit risks in respect of payments from third parties including under central and state government schemes, government corporations, insurance companies and third party administrators. If the company does not receive payments on a timely basis, its business, financial condition, results of operations, cash flows and prospects may be adversely affected.
Dr. Agarwal’s Health Care Limited IPO Subscription Status
| Investor Category | Subscription (times) | Shares Offered | Shares bid for | Total Amount (Rs Cr.) |
|---|---|---|---|---|
| Anchor | 1.00 | 2,17,78,798 | 2,17,78,798 | 875.51 |
| BHNI (10L+) | 0.31 | 72,59,600 | 22,85,955 | 91.9 |
| Employees | 0.27 | 15,79,399 | 4,19,510 | 16.86 |
| HNI | 0.39 | 1,08,89,400 | 42,80,535 | 172.08 |
| QIB | 4.64 | 1,45,19,201 | 6,73,61,280 | 2 |
| Retail | 0.41 | 2,54,08,599 | 1,03,42,430 | 415.77 |
| Share Holder | 0.51 | 11,29,574 | 5,76,765 | 23.19 |
| SHNI (2L - 10L) | 0.55 | 36,29,800 | 19,94,580 | 80.18 |
| Total | 1.55 | 5,35,26,173 | 8,29,80,520 | 3 |
Dr. Agarwal’s Health Care Limited IPO GMP
Last updated 24 Jan, 2025 · Source: aggregated grey-market dealers
| Date | IPO Price | GMP | Sub2 Sauda | Est. Listing | Est. Profit | Updated |
|---|---|---|---|---|---|---|
| 24 Jan, 2025 | 402 | ₹55▲ | 1500/22500 | ₹457 (13.68%) | - | 24 Jan, 2025 |
| 31 Jan, 2025 | 402 | ₹0▼ | -- | ₹402 (0.00%) | - | 31 Jan, 2025 |
| 01 Feb, 2025 | 402 | ₹1▲ | -- | ₹403 (0.25%) | - | 01 Feb, 2025 |
| 02 Feb, 2025 | 402 | ₹0▲ | -- | ₹402 (0.00%) | - | 02 Feb, 2025 |
| 03 Feb, 2025 | 402 | ₹-4 | -- | ₹398 (-1.00%) | - | 03 Feb, 2025 |
| 04 Feb, 2025 | 402 | ₹-4 | -- | ₹398 (-1.00%) | - | 04 Feb, 2025 |
Disclaimer: GMP is an unofficial signal from grey-market dealers and is not regulated by SEBI. Use it alongside subscription data and other research for informed decision-making.
How to Apply for Dr. Agarwal’s Health Care Limited IPO
Login to Your Trading App
Open Zerodha, Upstox, Groww, Angel One, or any brokerage app.
Go to IPO Section
Find Dr. Agarwal’s Health Care Limited under the IPO section. Select it and enter your bid details — choose lot size and price (cut-off price recommended).
Enter UPI ID and Submit
Provide your UPI ID linked to your bank account and submit the application.
Approve Mandate on UPI App
Open your UPI app (Google Pay, PhonePe, Paytm, BHIM) and approve the IPO payment request.
Application Confirmed
Your funds will be blocked in your account until the IPO allotment process is completed.